Nasopharyngeal carcinoma (NPC) · line 1 · Toripalimab + gemcitabine + cisplatin (JUPITER-02) — 1L recurrent/metastatic nasopharyngeal carcinoma
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-NPC-GC-TORIPALIMAB |
| ID | IND-NPC-1L-METASTATIC-GC-PD1 |
|---|---|
| Type | Indication |
| Status | reviewed 2026-07-11 |
| Diseases | DIS-NPC |
| Sources | SRC-CAPTAIN-1ST-YANG-2021 SRC-JUPITER-02-MAI-2021 SRC-NCCN-HNSCC-2025 |
Notes
STUB — draft entity pending Clinical Co-Lead sign-off (CHARTER §6.1; dev-mode-exempted). Coverage-enabling metastatic-1L indication for DIS-NPC. Numeric trial results throughout are approximate/recalled and explicitly flagged for verification against JUPITER-02 (Nat Med 2021) and CAPTAIN-1st (Lancet Oncol 2021) primary sources before any non-draft/clinical use.
Used By
Algorithms
ALGO-NPC-1L- ALGO-NPC-1L
Disease
DIS-NPC- Nasopharyngeal carcinoma (NPC)
Indication
IND-NPC-1L-LOCALLY-ADVANCED-CCRT- IND-NPC-1L-LOCALLY-ADVANCED-CCRT
Red flag
RF-NPC-EBV-DNA-POST-TREATMENT-SURVEILLANCE- Detectable or rising plasma EBV-DNA (BIO-EBV-DNA, quantitative PCR) after completion of d...
Regimen
REG-NPC-GC-CAMRELIZUMAB- Camrelizumab + gemcitabine + cisplatin (CAPTAIN-1st) — 1L recurrent/metastatic nasopharyn...REG-NPC-GC-TORIPALIMAB- Toripalimab + gemcitabine + cisplatin (JUPITER-02) — 1L recurrent/metastatic nasopharynge...